Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGY) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 55,395 shares, an increase of 102.6% from the April 30th total of 27,348 shares. Based on an average trading volume of 159,592 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are sold short.

Lonza Group Trading Down 0.6%

LZAGY stock traded down $0.36 during midday trading on Tuesday, hitting $62.97. The company’s stock had a trading volume of 104,693 shares, compared to its average volume of 88,834. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. Lonza Group has a twelve month low of $58.53 and a twelve month high of $73.85. The company’s fifty day moving average price is $63.10 and its 200 day moving average price is $65.85.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Lonza Group currently has a consensus rating of “Moderate Buy”.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.